Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells

Abstract

This chapter describes the requirements and preconditions for using human induced pluripotent cell lines in assay development within the pharmaceutical industry. The joint collaborative effort between academic and pharma partners within the StemBANCC consortium which enabled the implementation of iPSC-derived cellular models for drug discovery is highlighted. This large collaborative scientific network has successfully derived a significant number of well-characterized patient-specific iPSC lines and established disease-relevant cellular assays, both of which are requirements for enabling pharmaceutical companies to develop more efficacious and safer medicines.

Keywords: Differentiation protocols; Disease models; Induced pluripotent cell; iPSC.